Research desk · abstracts checked Oct 2026
PDRN research: what the skin studies actually show
Published PDRN research includes cell experiments, experimental skin models, human injection studies and reviews. This map uses PubMed abstracts to separate what researchers measured from what remains unestablished, especially for facial skincare products.
By the PDRN Today desk · Updated Oct 9, 2026 · 10 studies from PubMed · Not medical advice
In brief
- The wound-healing systematic review included laboratory, animal and clinical research.
- The polynucleotide esthetics review included nine studies covering 219 patients, rated low or moderate quality.
- The acne-scar trial enrolled 17 participants and tested injections, not serums.
- The nanoparticle study identifies poor skin delivery and degradation as limitations of PDRN.
What kind of evidence exists
PDRN research spans laboratory experiments, animal research, human studies and reviews, rather than a single body of facial-serum trials. The systematic review, “The effects of polydeoxyribonucleotide on wound healing and tissue regeneration,” included in vitro, in vivo and clinical studies. Its authors searched five databases through March 2020 and included 34 of more than 90 articles. That total describes eligible papers, not a patient count or a collection of equivalent clinical trials.
The human esthetics evidence includes small studies and a review that explicitly flags quality concerns. “The Effectiveness of Polynucleotides in Esthetic Medicine” included nine studies covering 219 patients, rated low or moderate quality. The review reports that injection areas and techniques varied. Its findings therefore need to be read alongside the treatment details; a result from one injection approach does not establish the same outcome for every formulation or use.
PDRN and polynucleotide terminology also needs checking before studies are grouped together. The molecular-definition review describes them as similar DNA-derived biopolymers and says interchangeable naming has caused confusion. It proposes a molecular-weight-based distinction, rather than establishing a universally accepted rule. Our PDRN versus polynucleotides guide explains that naming issue. For this evidence map, the material named in each abstract stays attached to that study's findings.
Wound healing and skin repair
Wound repair is a substantial theme in the supplied polydeoxyribonucleotide evidence. “Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing” reports local and systemic use, with findings involving cell migration, cell growth, new blood vessel formation and reduced inflammation. The review covers laboratory, animal and clinical research. Its focus is impaired wound healing, including changes associated with diabetes, thermal injury and ischemia—not a direct test of routine facial skincare.
The skin-cell study found different signaling responses in different cell types. In “Polydeoxyribonucleotide exerts opposing effects on ERK activity in human skin keratinocytes and fibroblasts,” researchers reported increased proliferation and migration in both cell types. They also found increased ERK phosphorylation and collagen accumulation in fibroblasts, but reduced ERK phosphorylation and inflammatory cytokine expression in keratinocytes. These are cell-level findings; they do not establish how much visible improvement a person would get from a serum.
The ginseng-derived PDRN study tested an experimental material in cells and artificial skin. Researchers produced Panax PDRN from tissue-cultured Korean ginseng roots and reported wound-healing and barrier-enhancement effects in their models, including KeraSkinTM. The authors suggested potential use for skin diseases, but that suggestion is not an established patient outcome. This abstract supports further investigation of plant-derived PDRN; it does not demonstrate the performance of a retail product.
Comparing serums? The Anua PDRN Hyaluronic Acid Capsule 100 Serum is $30.00 for 30 ml at the Anua US store (checked Oct 2026). See it at the store · affiliate link · or browse all 20 products.
Aging skin and skin quality
The polynucleotide review reports encouraging skin-quality results, with important limits on confidence. Its authors describe reductions in wrinkles and improvements in texture and elasticity, with statistically significant findings in several included studies. They also conclude that consensus on optimal use is limited and that rigorous, high-quality research is needed. These are findings about polynucleotide injections in the included studies, not established outcomes for a topical PDRN product.
The nanoparticle study investigated a delivery system, not PDRN alone. In “Polydeoxyribonucleotide-spermidine nanoparticles,” researchers combined PDRN with spermidine because they describe poor transdermal delivery and degradation as limitations. They reported increased cell migration and increased permeability in laboratory and in vivo testing. Those outcomes describe the engineered nanoparticles under study. They cannot be assigned to an ordinary serum simply because its label also lists PDRN.
The same nanoparticle paper reports a human efficacy evaluation, but the supplied abstract facts do not give its sample size. The researchers describe improvements in skin structure and function as anti-aging effects. Without the participant count, comparator, duration and detailed human outcomes in this brief, that finding cannot support a precise consumer expectation. If you are considering PDRN injections, discuss the procedure and its evidence with a board-certified dermatologist or licensed injector.
Scars, pigment and other uses
The acne-scar trial tested injections in a small, open-label study. “Air-Botulinum Neurotoxin and Polydeoxyribonucleotide Injections for Acne Scar Treatment” enrolled 17 participants and compared air-botulinum toxin, PDRN and their combination. Participants received treatment at baseline, Week 4 and Week 8, with follow-up at Week 16. The study reported POSAS scar-score reductions of 12.0 points for the combination, 9.0 for air-botulinum toxin and 6.1 for PDRN. The authors called for further research.
The pigmentation paper combines cell experiments with a very small clinical evaluation. “Novel Anti-Melanogenesis Properties of Polydeoxyribonucleotide” reported reduced melanin content in human melanocyte–keratinocyte cocultures treated with PDRN or Placentex. Its clinical evaluation involved six female patients with facial hyperpigmentation after three intradermal injection sessions, reporting more than noticeable improvement on a 5-point scale. The authors describe potential pigment-related properties; the abstract does not establish equivalent effects from topical skincare.
Under-eye concerns are not a single research outcome. The multispecialty under-eye review describes volume loss, pigment changes, vascular prominence and skin laxity as different contributors, and states that polynucleotides target texture and fine wrinkles. It concludes that treatment strategies need to be individualized. Likewise, the injection findings discussed in our PDRN for acne scars guide should not be read as evidence for every scar type or for a serum.
What is missing
A direct bridge from these studies to a particular facial serum is not established by the supplied abstracts. The molecular-definition review says PDRN/PN formulations are commercially available as gels, creams, serums, masks and injectables, but availability is not product-specific efficacy evidence. The nanoparticle paper identifies delivery and degradation limitations. Together, these facts make formulation and route questions central: the ingredient name alone does not show that a retail product reproduces a study's exposure or results.
More rigorous human esthetics research is explicitly needed, according to the polynucleotide systematic review. Its included studies were low or moderate quality, used varied injection techniques and left limited consensus on optimal use. The small acne-scar trial also calls for confirmation and protocol research. These abstracts do not establish long-term outcomes or the ideal treatment approach. Missing detail should remain missing, rather than being filled with an assumed schedule, dose or expected result.
Safety reports need the same limits as efficacy reports. The wound-healing reviews describe an absence of side effects, while the polynucleotide esthetics review describes generally mild, transient effects. The acne-scar trial reports mild swelling and redness. None of those statements establishes that every formulation or procedure is risk-free. Our PDRN side-effects guide provides context; questions about injections, allergies or skin conditions belong with a board-certified dermatologist or licensed injector.
How to read a study abstract
Start by identifying what was tested and where it was tested. The keratinocyte and fibroblast paper examined skin cells; the Panax PDRN paper used cells and artificial skin; the acne-scar trial treated people with injections. These settings answer different questions. When reading PDRN studies, keep the tested material, delivery route and experimental setting together before judging the conclusion. A finding about cell migration is not itself a measured improvement in facial wrinkles.
Next, check the study size, comparison and outcome measure. The acne-scar trial was randomized but open-label, enrolled 17 participants and used POSAS alongside satisfaction surveys and safety checks. The pigmentation evaluation reported six patients and a 5-point improvement scale. Those details are more informative than the word “improvement” alone. Ask what changed, how it was assessed and what comparison was available; do not substitute a cellular percentage for a human cosmetic result.
Finally, read a review's methods and limitations, not just its favorable conclusion. The wound-healing systematic review screened more than 90 articles and included 34; the esthetics review assessed quality and included nine low- or moderate-quality studies. Those counts describe different evidence collections, not interchangeable proof. For PDRN clinical trials and reviews alike, separate the authors' reported findings from their proposed applications, and leave conclusions about untested products unestablished.
Questions readers ask
Does PDRN actually work for skin?
The supplied studies report effects in specific settings, not a universal skincare result. The wound-healing review describes repair-related findings across laboratory, animal and clinical research. The polynucleotide esthetics review reports promising injection outcomes but rates its included studies low or moderate quality. Whether a particular facial serum delivers comparable benefits is not established by these abstracts.
Are there clinical trials on PDRN for acne scars?
Yes. A prospective, open-label, randomized trial enrolled 17 participants and compared PDRN injections, air-botulinum toxin injections and their combination. It reported a 6.1-point POSAS reduction with PDRN alone and the greatest improvement with the combination. The authors say further research is needed. This was an injection study, not a topical acne-scar product trial.
Do PDRN serums have the same evidence as injections?
The supplied abstracts do not establish equivalent results. The molecular-definition review lists both topical and injectable formulations, while the nanoparticle study identifies poor transdermal delivery and degradation as PDRN limitations. That paper reports a human evaluation of engineered PDRN-spermidine nanoparticles, but its findings cannot establish the performance of every serum containing PDRN.
Studies cited on this page
Numbers match the source marks in the text. Links go to the PubMed abstract.
- 1Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing.Pharmaceuticals (Basel, Switzerland) · 2021 · checked Oct 8, 2026
- 2Polydeoxyribonucleotide exerts opposing effects on ERK activity in human skin keratinocytes and fibroblasts.Molecular medicine reports · 2023 · checked Oct 8, 2026
- 3Analysis of Skin Regeneration and Barrier-Improvement Efficacy of Polydeoxyribonucleotide Isolated from Panax Ginseng (C.A. Mey.) Adventitious Root.Molecules (Basel, Switzerland) · 2023 · checked Oct 8, 2026
- 4Polydeoxyribonucleotide-spermidine nanoparticles: Preparation, characterization, and verification of skin anti-aging efficacy.International journal of biological macromolecules · 2025 · checked Oct 8, 2026
- 5The effects of polydeoxyribonucleotide on wound healing and tissue regeneration: a systematic review of the literature.Regenerative medicine · 2020 · checked Oct 8, 2026
- 6Novel Anti-Melanogenesis Properties of Polydeoxyribonucleotide, a Popular Wound Healing Booster.International journal of molecular sciences · 2016 · checked Oct 8, 2026
- 7The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review.Journal of cosmetic dermatology · 2025 · checked Oct 8, 2026
- 8What's New With Under Eye Treatment: A Multispecialty Systematic Review of Recent Under Eye Treatments.Dermatologic surgery: official publication for American Society for Dermatologic Surgery [et al.] · 2026 · checked Oct 8, 2026
- 9Air-Botulinum Neurotoxin and Polydeoxyribonucleotide Injections for Acne Scar Treatment.Aesthetic plastic surgery · 2025 · checked Oct 8, 2026
- 10From Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications of Multifunctional Biomolecules.Biomolecules · 2025 · checked Oct 8, 2026